{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:12:40Z","timestamp":1790482360136,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jaad.2017.04.005","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T10:25:09Z","timestamp":1494498309000},"page":"464-472.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients"],"prefix":"10.1016","volume":"77","author":[{"given":"Nausicaa","family":"Malissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Vergely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Roubertie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claire","family":"Malinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Bessis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jaad.2017.04.005_bib1","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","article-title":"Identification and characterization of the tuberous sclerosis gene on chromosome 16","volume":"75","year":"1993","journal-title":"Cell"},{"issue":"5327","key":"10.1016\/j.jaad.2017.04.005_bib2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","article-title":"Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34","volume":"277","author":"van Slegtenhorst","year":"1997","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.jaad.2017.04.005_bib3","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/jmg.33.11.962","article-title":"Loss of heterozygosity in tuberous sclerosis hamartomas","volume":"33","author":"Sepp","year":"1996","journal-title":"J Med Genet"},{"issue":"12","key":"10.1016\/j.jaad.2017.04.005_bib4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-4362.1998.00495.x","article-title":"Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance","volume":"37","author":"J\u00f3\u017awiak","year":"1998","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.04.005_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr Neurol"},{"issue":"5","key":"10.1016\/j.jaad.2017.04.005_bib6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/pde.12933","article-title":"Effect of angiofibromas on quality of life and access to care in tuberous sclerosis patients and their caregivers","volume":"33","author":"Crall","year":"2016","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.04.005_bib7","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bjd.12567","article-title":"First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex","volume":"169","author":"Tanaka","year":"2013","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2017.04.005_bib8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/0883073813488664","article-title":"A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex","volume":"28","author":"Wheless","year":"2013","journal-title":"J Child Neurol"},{"issue":"1","key":"10.1016\/j.jaad.2017.04.005_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/09546634.2010.489598","article-title":"Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin","volume":"23","author":"Kaufman McNamara","year":"2012","journal-title":"J Dermatol Treat"},{"issue":"3","key":"10.1016\/j.jaad.2017.04.005_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","article-title":"Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin","volume":"12","author":"Koenig","year":"2012","journal-title":"Drugs RD"},{"issue":"1","key":"10.1016\/j.jaad.2017.04.005_bib11","first-page":"15","article-title":"Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response","volume":"18","author":"Truchuelo","year":"2012","journal-title":"Dermatol Online J"},{"issue":"1","key":"10.1016\/j.jaad.2017.04.005_bib12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/archderm.148.1.138","article-title":"A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex","volume":"148","author":"Wataya-Kaneda","year":"2012","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2017.04.005_bib13","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/archdermatol.2011.254","article-title":"Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol","volume":"147","author":"DeKlotz","year":"2011","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.04.005_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-0960.2011.00837.x","article-title":"Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients","volume":"53","author":"Foster","year":"2012","journal-title":"Australas J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.04.005_bib15","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1365-2133.2011.10476.x","article-title":"Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1)) in two patients with tuberous sclerosis","volume":"165","author":"Mutizwa","year":"2011","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2017.04.005_bib16","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1468-3083.2011.04212.x","article-title":"Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma","volume":"26","author":"Salido","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2017.04.005_bib17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archdermatol.2010.125","article-title":"Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis","volume":"146","author":"Haemel","year":"2010","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.04.005_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ajd.12125","article-title":"Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions","volume":"55","author":"Tu","year":"2014","journal-title":"Australas J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.04.005_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/0019-5154.152516","article-title":"Facial angiofibromas of tuberous sclerosis treated with topical sirolimus in an Indian patient","volume":"60","author":"Vasani","year":"2015","journal-title":"Indian J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.04.005_bib20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ad.2011.02.019","article-title":"Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis","volume":"103","author":"Valer\u00f3n-Almaz\u00e1n","year":"2012","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"issue":"3","key":"10.1016\/j.jaad.2017.04.005_bib21","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/pde.12551","article-title":"Successful topical rapamycin treatment for facial angiofibromata in two children","volume":"32","author":"Pynn","year":"2015","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.04.005_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/0019-5154.174087","article-title":"Use of topical rapamycin in facial angiofibromas in Indian skin type","volume":"61","author":"Viswanath","year":"2016","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaad.2017.04.005_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2016.04.003","article-title":"Topical use of mammalian target of rapamycin (mTOR) inhibitors in tuberous sclerosis complex\u2014a comprehensive review of the literature","volume":"61","author":"J\u00f3\u017awiak","year":"2016","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.jaad.2017.04.005_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","article-title":"Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial","volume":"153","author":"Wataya-Kaneda","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2017.04.005_bib25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ad.2013.09.013","article-title":"Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis","volume":"105","author":"Kn\u00f6pfel","year":"2014","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"issue":"7","key":"10.1016\/j.jaad.2017.04.005_bib26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jamadermatol.2014.4298","article-title":"Clinical and histologic analysis of the efficacy of topical rapamycin therapy against hypomelanotic macules in tuberous sclerosis complex","volume":"151","author":"Wataya-Kaneda","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2017.04.005_bib27","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jamadermatol.2014.87","article-title":"Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin","volume":"150","author":"Muzic","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2017.04.005_bib28","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/j.1468-3083.2011.04304.x","article-title":"Association of glycerol and paraffin in the treatment of ichthyosis in children: an international, multicentric, randomized, controlled, double-blind study","volume":"26","author":"Blanchet-Bardon","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2017.04.005_bib29","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/jdv.12314","article-title":"Long-term emollient therapy improves xerosis in children with atopic dermatitis","volume":"28","author":"Boralevi","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2017.04.005_bib30","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/ced.12398","article-title":"Facial Angiofibroma Severity Index (FASI): reliability assessment of a new tool developed to measure severity and responsiveness to therapy in tuberous sclerosis-associated facial angiofibroma","volume":"39","author":"Salido-Vallejo","year":"2014","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.04.005_bib31","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaad.2015.07.018","article-title":"Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus","volume":"73","author":"Nathan","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.04.005_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1468-3083.2010.03685.x","article-title":"Development and evaluation of a Global Acne Severity Scale (GEA Scale) suitable for France and Europe","volume":"25","author":"Dr\u00e9no","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2017.04.005_bib33","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/jamadermatol.2014.5254","article-title":"Frequency of primary nonadherence to acne treatment","volume":"151","author":"Anderson","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.04.005_bib34","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jaad.2010.05.008","article-title":"A randomized controlled pilot study of strategies to increase adherence in teenagers with acne vulgaris","volume":"64","author":"Yentzer","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2017.04.005_bib35","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/hmg\/ddt597","article-title":"Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex","volume":"23","author":"Tyburczy","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.jaad.2017.04.005_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.1996.d01-923.x","article-title":"The cutaneous features of tuberous sclerosis: a population study","volume":"135","author":"Webb","year":"1996","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2017.04.005_bib37","doi-asserted-by":"crossref","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","article-title":"Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease","volume":"6","author":"Dabora","year":"2011","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.jaad.2017.04.005_bib38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2005.11.1072","article-title":"Acne in recipients of\u00a0renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects","volume":"55","author":"Mah\u00e9","year":"2006","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217304413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217304413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:44:07Z","timestamp":1759272247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217304413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0190962217304413"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.04.005","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}